Revolution Medicines (RVMD) EBITDA Margin (2019 - 2023)
Revolution Medicines' (RVMD) quarterly EBITDA Margin came in at 24256.47% in Q4 2023, down 2385394.0% year-on-year from N/an in Q4 2022, and down 752.57% quarter-over-quarter from 2845.11% in Q2 2023.
Revolution Medicines (RVMD) EBITDA Margin (2019 - 2023) Analysis & Trends
Revolution Medicines' EBITDA Margin history runs 5 years deep, the most recent figure standing at 24256.47% for Q4 2023.
- On a quarterly basis, EBITDA Margin fell 2385394.0% year-over-year to 24256.47% in Q4 2023; TTM through Sep 2024 was 88031.94%, a 8662217.0% decrease from a year earlier, with the FY2023 full-year figure at 4207.12%, down 347711.0% from the prior year.
- EBITDA Margin declined to 24256.47% in Q4 2023 per RVMD's latest filing, from 2845.11% in the prior quarter.
- Across five years, EBITDA Margin topped out at 79.26% in Q1 2019 and bottomed at 24256.47% in Q4 2023.
- The 5-year median for EBITDA Margin is 402.52% (2022), against an average of 2109.23%.
- Across the five-year window, EBITDA Margin surged 254813 bps in 2022 and sank 2385394 bps in 2023, its largest moves.
- Year by year, EBITDA Margin stood at 161.85% in 2019, then tumbled by 141 bps to 389.44% in 2020, then slumped by 44 bps to 559.33% in 2021, then increased by 28 bps to 402.52% in 2022, then slumped by 5926 bps to 24256.47% in 2023.
- Per Business Quant, the three latest RVMD EBITDA Margin figures stand at 24256.47% (Q4 2023), 2845.11% (Q2 2023), and 1071.53% (Q1 2023).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 30.35% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 23.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -24,256.47% |
| Jun 30, 2023 | -2,845.11% |
| Mar 31, 2023 | -1,071.53% |
| Dec 31, 2022 | -402.52% |
| Sep 30, 2022 | -2,280.48% |
| Jun 30, 2022 | -681.10% |
| Mar 31, 2022 | -764.70% |
| Dec 31, 2021 | -559.33% |
| Sep 30, 2021 | -4,828.61% |
| Jun 30, 2021 | -512.01% |
| Mar 31, 2021 | -369.13% |
| Dec 31, 2020 | -389.44% |
| Sep 30, 2020 | -217.61% |
| Jun 30, 2020 | -279.14% |
| Mar 31, 2020 | -182.59% |
| Dec 31, 2019 | -161.85% |
| Sep 30, 2019 | -108.42% |
| Jun 30, 2019 | -85.99% |
| Mar 31, 2019 | -79.26% |